Key Takeaways:
Zealand Pharma shares plunged more than 20% in early trading Monday after clinical trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than rival treatments.
The decline wiped out billions in market capitalization for the Danish biotech, which had been positioning survodutide as a contender in the rapidly expanding weight-loss drug market. The company did not immediately comment on the results.
Survodutide, a glucagon receptor/GLP-1 receptor dual agonist, is being developed for obesity and related metabolic conditions. The trial data, presented over the weekend, showed gastrointestinal adverse events and discontinuation rates that exceeded those reported for established treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
The setback comes at a critical time for Zealand, which has been seeking to carve out a niche in the obesity space alongside its partnered asset petrelintide, an amylin analog developed with Roche. Petrelintide posted more favorable tolerability data at the American Diabetes Association conference last week, with 10.7% weight loss and low discontinuation rates.
The survodutide results create a stark contrast within Zealand's pipeline. While the Roche-partnered amylin program advances toward Phase 3, survodutide's safety profile now casts doubt on its ability to compete in a market dominated by incretin-based therapies with established efficacy and tolerability.
The decline puts Zealand shares at their lowest level in months, testing support levels not seen since before the company's obesity pipeline gained momentum. Investors will watch for any regulatory implications or trial modifications that Zealand may announce in the coming days.
This article is for informational purposes only and does not constitute investment advice.
